Business

NEW YORK—In 2002, Don Brockman was diagnosed with amyloidosis. The following year, he and his wife launched the nonprofit Amyloidosis Foundation, and in 2007,…

Accurate identification of the amyloid fibril protein is the critical first step in the diagnostic pathway for any patient with amyloidosis.Service Overview …

The American Society of Hematology (ASH) has published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of light chain…

Amyloidosis Market Global Outlook, Country Deep-Dives & Strategic Opportunities (2024-2033) Market size (2024): USD 1.2 billion · Forecast (2033): 1.20 Billion…

A new study published in Open Heart provided up-to-date data on the epidemiology of amyloid transthyretin (ATTR) amyloidosis in the US. “Our findings…

AbstractAmyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac…

Not intended for UK MediaBayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance…

AbstractBackgroundAcquired transthyretin (ATTR) amyloidosis is increasingly reported among domino liver transplantation (DLT) recipients who receive livers from…

Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…

– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five pending patients,…